The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW),  led by Murdoch Children’s Research Institute (MCRI) Chief Scientist  Professor Melissa Little  AC, has released its  2024 annual report.

reNEW is a global consortium that focuses on translating stem cell science into therapies at its three research nodes, the University of Copenhagen, Leiden University Medical Center, and Murdoch Children's Research Institute in Melbourne.

Image: reNEW CEO and MCRI Chief Scientist Professor Melissa Little

“The one word that captures 2024 for reNEW is progress,” reNEW CEO Professor Little said. 

“The critical mass and increased opportunities created within reNEW has proven to be extremely powerful. Internal and external partnerships enable us to create more than the sums of the parts.”

The 2024 Report captures the significant strides reNEW has made in advancing its scientific research, enhancing engagement and communication efforts and fostering collaborative partnerships to develop potential products.

It also lists 105 publications authored by reNEW researchers, out of which three stood out for their groundbreaking contributions to their respective fields including a world-first blood stem cell breakthrough led by MCRI’s Associate Professor Elizabeth Ng in collaboration with Professors Andrew Elefanty and Ed Stanley, published in Nature Biotechnology. 

The other standout publications came from Professor Josh Brickman from the University of Copenhagen and Professor Ton Rabelink from the Leiden University Medical Center. 

Learn more about the work  MCRI researchers in the reNEW Melbourne node  are undertaking.